Quaternary Pumps Transfer Shear-Sensitive Biopharmaceuticals

Article

The Quattroflow QF20KSU single-use quaternary pump for biopharmaceutical processing reduces contamination risk and downtime.

Quattroflow QF1200-HT single- and multi-use pumps. Image courtesy of PSG.

Quattroflow, part of PSG, a Dover company, will introduce the new QF20KSU single-use pump at INTERPHEX in Booth No. 2253. The pump features replaceable polypropylene wetted pump chambers, which can be easily replaced as a complete unit between batches to eliminate sterilization, lower cross-product contamination risk, and reduce downtime. The QF20KSU features flow rates of 200–16,000 Lph (53–4227 gph), 51 mm (2 in.) connections, and autoclave and gamma irradiation capabilities.

Quattroflow QF1200-HT single- and multi-use pumps have a high turndown ratio for precise accuracy in controlling flow rates. Their compact design with integrated controller provides a plug-and-play solution for applications requiring precision flow control, quick batch changes, and a small footprint. The QF1200-HT offers flow rates of 6–1200 Lph (1.6–317 gph) and 19-mm (3/4 in.) connections.

Quattroflow pumps are used in a wide range of biopharmaceutical applications requiring gentle product handling, high containment, low pulsation, purity, and cleanability. Unlike peristaltic and lobe pumps, Quattroflow quaternary pumps use no moving parts to provide non-slip operation, which is optimal for transferring shear-sensitive products without damage, while virtually eliminating particle generation and heat degradation. The pumps are self-priming, provide safe dry-run operation, and allow for clean-in-place (CIP), sterilize-in-place (SIP), and autoclave capabilities.

Source: PSG

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content